Abstract:1 T here is a relationship between sphingolipid de novo bio-synthesis and nonalcoholic fatty liver disease or hepatic steatosis. 1 However, the mechanism is still unclear because many sphingolipids may be involved in fatty liver formation. Sphingomyelin synthase (SMS), which uses ceramide as one of the substrates to produce sphingomyelin, sits at the crossroads of sphingolipid biosynthesis. Overexpression or blockage of SMS activity should influence not only sphingomyelin but also ceramide levels. 2 SMS has 2 isoforms: SMS1 and SMS2. The major isoform in the liver is SMS2. Ceramide is composed of sphingosine and a fatty acid. Ceramide can be generated through the de novo pathway. 4 It also can be generated through the sphingomyelinase pathway, which breaks down sphingomyelin in the cell membranes and releases ceramide. 5 Roles have been proposed for ceramide in heart disease, and it has been shown to induce apoptosis. 6 Ceramide mediates an inflammatory response initiated by cytokines or oxidized low-density lipoprotein, a response that upregulates adhesion molecule expression and induces adhesion and migration of monocytes. These events are crucial in the initiation and progression of atherogenesis. 7,8 Plasma ceramide may contribute to maladaptive inflammation in patients with coronary heart disease. 9 It has been reported that plasma ceramide levels in apolipoprotein E knockout (KO) mice are higher than in controls. 10 Plasma ceramides may also correlate with oxidized low-density lipoprotein, becoming a risk factor for atherosclerosis. 10 CD36 is a member of the class B scavenger receptor family , located on cell surface lipid rafts. 11 CD36 expression is increased concomitantly with hepatic TG content in different animal models of liver steatosis. 12,13 CD36 is regulated by proliferator-activated receptor (PPAR) γ. 14 PPARγ and CD36 mRNA expression is specifically upregulated in high-fat diet– induced liver steatosis in mice. 15 PPARγ is a member of a nuclear hormone superfam-ily that heterodimerizes with the retinoid X receptor. These Objective—Sphingolipid de novo biosynthesis is related to nonalcoholic fatty liver disease or hepatic steatosis. However, the mechanism is still unclear. Sphingomyelin synthase (SMS), using ceramide as one of the substrates to produce sphingomyelin, sits at the crossroads of sphingolipid biosynthesis. SMS has 2 isoforms: SMS1 and SMS2. SMS2 is the major isoform in liver. Approach and Results—To investigate the relationship between liver SMS2 activity–mediated sphingolipid changes and hepatic steatosis, we used 2 mouse models: SMS2 liver-specific transgenic and SMS2 knockout mice. We found that SMS2 liver-specific transgenic …

Impact of Sphingomyelin Synthase 1 Deficiency on Sphingolipid Metabolism and Atherosclerosis in Mice

Macrophage Sphingomyelin Synthase 2 Deficiency Decreases Atherosclerosis in Mice

Effect of Liver Total Sphingomyelin Synthase Deficiency on Plasma Lipid Metabolism.

Sphingomyelin Synthase 2 is One of the Determinants for Plasma and Liver Sphingomyelin Levels in Mice

Abstract 410: Effect of Total Sphingomyelin Synthase Activity on Low Density Lipoprotein Catabolism

Sphingomyelin Synthase 2 Deficiency Decreases Atherosclerosis and Inhibits Inflammation in Mice

Effect of Total SMS Activity on LDL Catabolism in Mice.

Inhibition of Sphingomyelin Synthase (SMS) Affects Intracellular Sphingomyelin Accumulation and Plasma Membrane Lipid Organization.

Sphingomyelin Synthase 2 Activity and Liver Steatosis

Selective Reduction in the Sphingomyelin Content of Atherogenic Lipoproteins Inhibits Their Retention in Murine Aortas and the Subsequent Development of Atherosclerosis.

Liver Sphingomyelin Synthase 1 Deficiency Causes Steatosis, Steatohepatitis, Fibrosis, and Tumorigenesis: an Effect of Glucosylceramide Accumulation

Abstract 236: Impact on Smsr, As A Pe-plc, on Nash and Liver Fibrosis

Sphingomyelin Synthase–related Protein SMSr is a Phosphatidylethanolamine Phospholipase C That Promotes Nonalcoholic Fatty Liver Disease

Alterations to Sphingomyelin Metabolism Affect Hemostasis and Thrombosis

Sphingomyelin Synthases 1 and 2 Exhibit Phosphatidylcholine Phospholipase C Activity

Sphingomyelin Synthase 2 Activity and Liver Steatosis an Effect of Ceramide-Mediated Proliferator-Activated Receptor Γ 2 Suppression

The Sphingomyelin Synthase Family: Proteins, Diseases, and Inhibitors

Sphingomyelin Synthase 2 Deficiency Attenuates Nf Kappa B Activation

Adenovirus-Mediated Overexpression of Sphingomyelin Synthases 1 and 2 Increases the Atherogenic Potential in Mice

Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation

Pharmacologic Inhibition of Sphingomyelin Synthase (SMS) Activity Reduces Apolipoprotein-B Secretion from Hepatocytes and Attenuates Endotoxin-Mediated Macrophage Inflammation.